Antithrombin-lowering in hemophilia: a closer look at fitusiran
Por um escritor misterioso
Descrição
Full article: An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B
PDF) An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B
Hemophilia as a blueprint for gene therapy
Fitusiran prophylaxis 'great option' for reducing bleeds in people with hemophilia A or B
PDF) An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B
Fitusiran Emerges as a Potential Pan-Hemophilia Rebalancing Agent
Summer 2022 haemophilia trial update - European Pharmaceutical Review
A Molecular Revolution in the Treatment of Hemophilia: Molecular Therapy
Pharmaceuticals, Free Full-Text
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial - The Lancet Haematology
Innovations in Managing Hemophilia
Fitusiran Reduces Bleeding in Hemophilia A, B, Regardless of Inhibitors
Positive Phase III results for fitusiran in hemophilia
WO2021262695A1 - Methods and compositions for treating hemophilia - Google Patents
Antithrombin-lowering in hemophilia: a closer look at fitusiran - ScienceDirect
de
por adulto (o preço varia de acordo com o tamanho do grupo)
:max_bytes(150000):strip_icc()/5351973-c6293b44c0fe481b9ae2920e31b5bc74.jpg)
